These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 16609301)

  • 1. Asymmetric dimethylarginine: a new player in the pathogenesis of renal disease?
    Zoccali C; Kielstein JT
    Curr Opin Nephrol Hypertens; 2006 May; 15(3):314-20. PubMed ID: 16609301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Asymmetric dimethylarginine: metabolism, arginine paradox, pathophysiology].
    Gilinskiĭ MA
    Usp Fiziol Nauk; 2007; 38(3):21-39. PubMed ID: 17977229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asymmetric dimethylarginine may be a missing link between cardiovascular disease and chronic kidney disease.
    Ueda S; Yamagishi S; Kaida Y; Okuda S
    Nephrology (Carlton); 2007 Dec; 12(6):582-90. PubMed ID: 17995585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease.
    Bode-Böger SM; Scalera F; Kielstein JT; Martens-Lobenhoffer J; Breithardt G; Fobker M; Reinecke H
    J Am Soc Nephrol; 2006 Apr; 17(4):1128-34. PubMed ID: 16481412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asymmetric dimethylarginine (ADMA): the silent transition from an 'uraemic toxin' to a global cardiovascular risk molecule.
    Fliser D
    Eur J Clin Invest; 2005 Feb; 35(2):71-9. PubMed ID: 15667575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-Arginine therapy in cardiovascular pathologies: beneficial or dangerous?
    Böger RH
    Curr Opin Clin Nutr Metab Care; 2008 Jan; 11(1):55-61. PubMed ID: 18090660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function.
    Richir MC; Bouwman RH; Teerlink T; Siroen MP; de Vries TP; van Leeuwen PA
    JPEN J Parenter Enteral Nutr; 2008; 32(6):613-21. PubMed ID: 18974239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes.
    Yamagishi S; Ueda S; Okuda S
    Med Hypotheses; 2007; 69(4):922-4. PubMed ID: 17368960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arginine, arginine analogs and nitric oxide production in chronic kidney disease.
    Baylis C
    Nat Clin Pract Nephrol; 2006 Apr; 2(4):209-20. PubMed ID: 16932427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The endothelium as a target in renal diseases.
    Zoccali C
    J Nephrol; 2007; 20 Suppl 12():S39-44. PubMed ID: 18050141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated plasma concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine in citrullinemia.
    Lücke T; Tsikas D; Kanzelmeyer N; Vaske B; Das AM
    Metabolism; 2006 Dec; 55(12):1599-603. PubMed ID: 17142130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease - possible candidates for paradoxical epidemiology?
    Busch M; Fleck C; Wolf G; Stein G
    Amino Acids; 2006 May; 30(3):225-32. PubMed ID: 16680555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levels of asymmetric dimethylarginine, nitric oxide and lipid peroxidation markers in patients with end-stage renal disease having peritoneal dialysis treatment.
    Göçmen AY; Sahin E; Koçak H; Tuncer M; Gümüşlü S
    Clin Biochem; 2008 Jul; 41(10-11):836-40. PubMed ID: 18457672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of asymmetrical dimethylarginine in the progression of renal disease.
    Raptis V; Kapoulas S; Grekas D
    Nephrology (Carlton); 2013 Jan; 18(1):11-21. PubMed ID: 23016674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease.
    Ueda S; Yamagishi SI; Matsumoto Y; Fukami K; Okuda S
    Clin Exp Nephrol; 2007 Jun; 11(2):115-121. PubMed ID: 17593510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effects of endogenous L-arginine analogues on nitric oxide synthesis in platelets: role in platelet hyperaggregability in hypertension.
    de Meirelles LR; Mendes-Ribeiro AC; Santoro MM; Mendes MA; da Silva MN; Mann GE; Brunini TM
    Clin Exp Pharmacol Physiol; 2007 Dec; 34(12):1267-71. PubMed ID: 17973865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nitric oxide deficiency in chronic kidney disease.
    Baylis C
    Am J Physiol Renal Physiol; 2008 Jan; 294(1):F1-9. PubMed ID: 17928410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asymmetric Dimethylarginine (ADMA) in cardiovascular and renal disease.
    Alpoim PN; Sousa LP; Mota AP; Rios DR; Dusse LM
    Clin Chim Acta; 2015 Feb; 440():36-9. PubMed ID: 25444745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal parenchymal disease and hypertension.
    Preston RA; Epstein M
    Semin Nephrol; 1995 Mar; 15(2):138-51. PubMed ID: 7777724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of nitric oxide-producing and -degrading pathways in coronary endothelial dysfunction in chronic kidney disease.
    Tatematsu S; Wakino S; Kanda T; Homma K; Yoshioka K; Hasegawa K; Sugano N; Kimoto M; Saruta T; Hayashi K
    J Am Soc Nephrol; 2007 Mar; 18(3):741-9. PubMed ID: 17267746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.